Efficacy, safety and tolerability of a delamanid-containing regimen for 24 weeks in the treatment of multidrug-resistant-tuberculosis and extensively drug resistant (XDR-TB)

Trial Profile

Efficacy, safety and tolerability of a delamanid-containing regimen for 24 weeks in the treatment of multidrug-resistant-tuberculosis and extensively drug resistant (XDR-TB)

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Nov 2017

At a glance

  • Drugs Delamanid (Primary)
  • Indications Tuberculosis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Nov 2017 New trial record
    • 23 Oct 2017 Interim results (n=32) published in the Journal of Antimicrobial Chemotherapy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top